NIMG-37. DELAYED PSEUDOPROGRESSION IN TWO PATIENTS UNDERGOING TTFIELDS TREATMENT FOR NEWLY DIAGNOSED GLIOBLASTOMA

PURPOSE: Tumor treatment fields (TTFields) are approved by the FDA for newly diagnosed as well as recurrent glioblastoma (GBM). TTFields have been shown to extend survival by 4.9 months in newly diagnosed GBM, and a landmark overall survival rate of 13% at 5 years. However, the specific effects rema...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neuro Oncol
Päätekijät: Lowman, Allison, Hurrell, Sarah, Bobholz, Samuel, Connelly, Jennifer, Cochran, Elizabeth, Mueller, Wade, McGarry, Sean, Brehler, Michael, LaViolette, Peter
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2020
Aiheet:
Neuroimaging
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651686/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.650
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia